ArticleJournal of the American Academy of Dermatology2023

Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study.

Bonnie W Leung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.